Demographics and baseline characteristics
| Characteristic | Cohort A1 (n=88) |
| Age, median (range), years | 63.0 (41–80) |
| ECOG performance status, n (%) | |
| 0 | 40 (45.5) |
| 1 | 48 (54.5) |
| Disease stage at diagnosis, n (%) | |
| I | 28 (31.8) |
| II | 7 (8.0) |
| III | 37 (42.0) |
| IV | 16 (18.2) |
| Histology, n (%) | |
| Endometrioid carcinoma type I | 58 (65.9) |
| Endometrial carcinoma type II | 30 (34.1) |
| Serous | 4 (4.5) |
| Clear cell | 1 (1.1) |
| Undifferentiated | 3 (3.4) |
| Mixed | 5 (5.7) |
| Unspecified | 14 (15.9) |
| Other* | 3 (3.4) |
| Number of prior lines of therapy, n (%)† ‡ | |
| 1 | 57 (64.8) |
| 2 | 25 (28.4) |
| ≥3 | 6 (6.8) |
| Progression-free interval from last platinum treatment, median (range), months | 7.1 (0.2–123.0) |
*Includes adenocarcinoma, endometrial adenocarcinoma, and endometrioid carcinoma.
†All patients received at least one line of prior anti-cancer therapy.
‡Includes lines of therapy prior to the advanced/recurrent setting.
ECOG, Eastern Cooperative Oncology Group.